Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Atara Biotherapeutics Inc (ATRA) USD0.0001

Sell:$16.04 Buy:$16.05 Change: $0.21 (1.32%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$16.04
Buy:$16.05
Change: $0.21 (1.32%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$16.04
Buy:$16.05
Change: $0.21 (1.32%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Contact details

Address:
611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO
94080-7015
United States
Telephone:
+1 (650) 2788930
Website:
www.atarabio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ATRA
ISIN:
US0465131078
Market cap:
$1.36 billion
Shares in issue:
84.76 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ronald Renaud
    Chairman of the Board
  • Pascal Touchon
    President, Chief Executive Officer, Director
  • Utpal Koppikar
    Chief Financial Officer, Senior Vice President
  • Joseph Newell
    Chief Operating Officer, Executive Vice President
  • Jakob Dupont
    Executive Vice President, Global Head of Research and Development
  • K. Amar Murugan
    Senior Vice President, General Counsel
  • Kristin Yarema
    Senior Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.